Speculation Heats Up on Amarin (AMRN) After Sales Force Hiring Delayed

November 29, 2012 8:54 AM EST Send to a Friend
Amarin Corp Plc (NASDAQ: AMRN) is higher early Thursday amid news the company is delaying the hiring of a sales force until December versus November.

While on the surface this news would seem neutral-to-negative, speculators view this as an indications that talks with large pharma companies about a buyout or partnership to launch Vascepa are moving in the right direction. Also, this could indicate an NCE decision from the FDA is imminent. NCE status would likely push suitors over the top, although many analysts aren't certain it will be granted.

With or without a partnership or takeover, Amarin said today it continues to anticipate the launch of Vascepa early in the first quarter of 2013.

Shares of AMRN last traded at $12.07, up 1.6 percent.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

FDA, Rumors, Trader Talk

Add Your Comment